Next Article in Journal
Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma
Next Article in Special Issue
Local Recurrence and Development of Spinal Cord Syndrome during Follow-Up after Surgical Treatment of Metastatic Spine Disease
Previous Article in Journal
Chemoradiotherapy for Head and Neck Cancer
Previous Article in Special Issue
Investigating microRNA Profiles in Prostate Cancer Bone Metastases and Functional Effects of microRNA-23c and microRNA-4328
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Management of Metastatic Spinal Cord Compression in Routine Clinical Practice

by
Luis Alberto Pérez-Romasanta
1,2,*,†,
Estanislao Arana
2,3,†,
Francisco M. Kovacs
2,4 and
Ana Royuela
2,5
1
Department of Radiation Oncology, Hospital Universitario de Salamanca, Instituto de Investigaciones Biomédicas de Salamanca (IBSAL), 37007 Salamanca, Spain
2
Spanish Back Pain Research Network (REIDE), 28008 Madrid, Spain
3
Department of Radiology, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain
4
Back Pain Unit, HLA-Moncloa University Hospital, 28008 Madrid, Spain
5
Clinical Biostatistics Unit, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Consorcio de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28222 Madrid, Spain
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2023, 15(10), 2821; https://doi.org/10.3390/cancers15102821
Submission received: 14 March 2023 / Revised: 4 April 2023 / Accepted: 16 May 2023 / Published: 18 May 2023

Abstract

:

Simple Summary

Most Spanish specialists involved in the clinical management of spinal cord compression are familiar with the scoring systems for spine instability and spinal compression as well as with the NICE guideline recommendations. However, many do not apply them in routine practice. Scores on the scales used to evaluate spine instability in neoplastic diseases were interpreted correctly by 57.5–70.0% of the practitioners while scores of the spinal cord compression grading system were interpreted correctly by 30.0–37.5%. There is room for improvement in the management of SMD in routine practice.

Abstract

(1) Background: Whether clinical management of spinal metastatic disease (SMD) matches evidence-based recommendations is largely unknown. (2) Patients and Methods: A questionnaire was distributed through Spanish Medical Societies, exploring routine practice, interpretation of the SINS and ESCC scores and agreement with items in the Tokuhashi and SINS scales, and NICE guideline recommendations. Questionnaires were completed voluntarily and anonymously, without compensation. (3) Results: Eighty specialists participated in the study. A protocol for patients with SMD existed in 33.7% of the hospitals, a specific multidisciplinary board in 33.7%, 40% of radiological reports included the ESCC score, and a prognostic scoring method was used in 73.7%. While 77.5% of the participants were familiar with SINS, only 60% used it. The different SINS and ESCC scores were interpreted correctly by 57.5–70.0% and 30.0–37.5% of the participants, respectively. Over 70% agreed with the items included in the SINS and Tokuhashi scores and with the recommendations from the NICE guideline. Differences were found across private/public sectors, hospital complexity, number of years of experience, number of patients with SMD seen annually and especially across specialties. (4) Conclusions: Most specialists know and agree with features defining the gold standard treatment for patients with SCC, but many do not apply them.

1. Introduction

Spinal metastases are the most common type of bone metastasis [1,2]. Spinal metastatic disease can lead to bone fracture, instability, and metastatic spinal cord compression (MSCC). The latter is a devastating complication, which appears in 2.5–10.0% of patients with cancer and 40% of those with bone metastases [3,4]. The prognosis of MSCC is better if it is treated before paresis appears, but 50% of patients lose the ability to walk before they get diagnosed [1,5,6].
Timely and efficient coordination among different specialists is paramount for appropriate treatment [2]. To this end, several standardized methods have been developed [7,8,9,10,11]. However, whether these methods are actually used in routine clinical practice is largely unknown. In fact, audits have reported inconsistencies between recommendations of clinical guidelines issued by the National Institute for Health and Care Excellence (NICE) and actual routine practice in the United Kingdom and Ireland [12,13,14].
The objective of this study was to explore the management of MSCC in routine practice in Spain and to assess whether it followed available evidence-based recommendations.

2. Materials and Methods

A questionnaire was distributed to specialists involved in the clinical management of MSCC.

2.1. Subjects

All physicians treating patients with MSCC in Spain were welcome to complete the questionnaire. An invitation was sent to all members of the Spanish scientific societies representing Medical Oncology (“SEOM”—3035 members), Radiation Oncology (“SEOR”—1201 members), Radiology (“SERAM”—6024 members), Neurosurgery (“SENEC”—795 members) Orthopedic Surgery (“SECOT”—5120 members), and clinicians specialized in spine conditions (including neurosurgeons and orthopedic surgeons) (“GEER”—303 members).

2.2. Questionnaire

The questionnaire (Appendix A) gathered information on the participant’s characteristics, work setting, clinical practice, and familiarity with the methods for management of MSCC.
Participants’ characteristics included age (date of birth); medical specialty; seniority (in-training/certified specialist); number of years of clinical practice since certification; and number of patients with MSCC managed during the last 12 months.
Data on work setting included: private/public sector (“National Health Service” or “NHS” if healthcare was funded by taxpayers or “private” if funded by patients or private insurance companies) and data on the hospital in which the clinician worked; ownership (NHS/other governmental institutions/non-profit private institutions/for-profit private companies); management (NHS/private); whether it treated patients covered by the NHS; whether radiological reports quantified compression according to the Epidural Spinal Cord Compression (ESCC) scale [15] (always/occasionally/no); whether a protocol for management of patients with MSCC was implemented and, if so, whether it was multidisciplinary; whether a Board to coordinate care for patients with MSCC existed and, if so, which specialties were included; and hospital complexity (based on number of beds and physicians, academic activity, use of high technology, and performance of highly complex procedures, according to the classification established by the Spanish National Health Service, where Category 1 is the simplest and Category 5 is the most complex) [16].
Data on clinical practice related to MSCC included: method/s used to predict life-expectancy of patients with MSCC, if any (Tokuhashi—original or modified/Bauer—original or modified/Tomita/van der Linden/other); imaging procedure/s used to assess MSCC (entire spine MRI/MRI of the vertebral segment involved/scanner/scanner of the segment involved/other); familiarity with the Spine Instability Neoplastic Score (SINS) [17]; and use of SINS in routine practice (systematically/occasionally/no).
Participants were also asked to interpret the meaning of “1b” and “2” scores on the ESCC scale and “3”, “10”, and “15” on the SINS.
Finally, respondents were requested to rate their degree of agreement (from 1—strongly disagree to 5—strongly agree) with 18 statements; six focused on the prognostic value of items included in the modified Tokuhashi scale [18] (oncological prognosis, number of spinal metastases, score in general performance tools such as Karnofsky Performance Score or the Eastern Cooperative Oncology Group Score [18,19], visceral metastases, type–location of primary tumor, and degree of paresis). Five statements focused on spine instability [4] (mechanical pain, type of bone lesion—blastic, lytic, or mixed, spinal alignment, degree of vertebral body collapse, and involvement of facet joints). Last seven statements were recommendations from the NICE DG75 clinical guideline for assessment of MSCC (“NICE guideline”) [6,12] (use of MRI, use of full spine MRI to assess MSCC, neurologic examination, assessment by all treating clinicians, and clinical assessment of pain, sphincter control, and limb strength and sensitivity).

2.3. Procedure

The authors shared the protocol of the study, but not the questionnaire, with representatives of the SEOM, SEOR, SERAM, SENEC, SECOT, and GEER. These societies forwarded the invitation to participate and a link to the questionnaire to all their members. SENEC and GEER sent an email to all their members, followed by a reminder 1 month later. The other societies published the information in their websites. Members affiliated to two societies (e.g., a neurosurgeon affiliated to SENEC and GEER) were invited twice.
Participants agreed to complete the questionnaire only once and alone, with no help from other colleagues, and to answer the questions without checking with the literature or colleagues.
The questionnaire was hosted in Google Forms. No data allowing to identify participants were requested. However, name was requested for those wishing to be informed of the study results. It had been planned that if two respondents coincided in their date of birth and specialty or shared the same IP address, only the first answers introduced would be analyzed. However, this situation did not occur.
Neither respondents nor the scientific societies received any compensation for their contribution to the study.
Results from the questionnaire were stored in an ad hoc database using Microsoft Excel v365.

2.4. Analysis

Categorical variables were described by their absolute and relative frequencies. Continuous variables were described by their median, P25, P75, and range values.
Answers on agreement were collapsed into “disagree” (answers 1 to 3) and “agree” (answers 4–5). Answers on clinical practice, interpretation of the SINS and ESCC scores, and agreement with statements were compared across specialties, number of patients treated annually (categorized as ≤7, 8–13, and ≥14), years of experience (categorized as ≤7, 8–13 y, ≥14), private/public sector (working for the NHS vs. privately vs. both), and hospital complexity level (categorized as “simple”—categories 1–3 vs. “complex”—categories 4–5). Comparisons across specialties were restricted to those with ≥5 participants.
For comparisons, the chi-square or Fisher’s exact tests were used for categorical variables and Mann-Whitney’s U or Kruskall–Wallis tests for numerical ones. Signification was set at 0.05. The statistical package Stata/IC v.16 (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX, USA: StataCorp LLC) was used.

3. Results

Between 1st June and 30th October 2021, 80 clinicians completed the questionnaire.

3.1. Participant’s Characteristics

The typical participant was a 46-year-old certified specialist, who treated annually ≥14 patients with MSCC and had been working for the NHS for 13 years in a grade 4 complexity level hospital, which was owned and managed by the NHS (Table 1).
Management protocols for MSCC were implemented in hospitals where 31 participants (38.8%) worked; thirty were multi-disciplinary. A multidisciplinary board for MSCC existed in 27 (33.8%) hospitals and included between two and six specialties (Table 1). Those more commonly represented were medical oncology, radiation oncology, and orthopedic surgery.
Boards were more common in hospitals where specialists worked both privately and for the NHS (56.0%) than in those where they worked only for the NHS (25.0%) or privately (14.2%) (p = 0.020). No other differences related to protocols or boards were found across specialties, number of patients treated annually, years of experience, private/public sector, and hospital complexity level.

3.2. Clinical Practice

Full-spine MRI (71.3%) and MRI of the involved segment (22.5%) were the most commonly used imaging procedures for assessing MSCC. Most participants (73.8%) used a prognostic method, although 15.0% used it only occasionally. The Tokuhashi was the most common one (27.5%), but in 33.8% of the hospitals, the scoring system varied across Departments (Table 2).
The SINS was known by 77.5% of the participants. It was known to more specialists working in “complex” hospitals (88.7%) than in “simple” ones (55.6%) (p = 0.002) and to orthopedic surgeons (87.5%) and radiation oncologists (85.0%) than neurosurgeons (66.7%) and medical oncologists (50.0%) (p = 0.005).
The SINS was used routinely by 60.0% of specialists. Its use was more common among specialists working in “complex” (71.7%) than “simple” hospitals (37.0%) (p = 0.007), among physicians working privately (71.4%) or privately and for the NHS (76.0) than among those working only for the NHS (50.0%) (p = 0.019), and among orthopedic surgeons (81.3%), neurosurgeons (66.7%), and radiation oncologists (55.0%) than among medical oncologists (22.2%) (p = 0.000).
No other differences in these variables were found across specialties, number of patients treated annually, years of experience, private/public sector, and hospital complexity level.

3.3. Accurate Interpretation of Scores

The different SINS and ESCC scores were correctly interpreted by 57.5–70.0% and 30.0–37.5% of the participants, respectively (Table 3).
The proportion of specialists who interpreted the SINS score correctly was lower among medical oncologists (27.8–44.4%) than among radiation oncologists (55.0–70.0%), neurosurgeons (66.7%), and orthopedic surgeons (68.8–81.3%). These differences were significant for a score of three (p = 0.017) and 10 (p = 0.041) and came close to statistical significance for a score of 15 (p = 0.064) (Table 3).
The correct interpretation of a “1b” ESCC score was more common among orthopedic surgeons (46.9%) than neurosurgeons (16.7%), medical oncologists (16.7%), and radiation oncologists (15.0%) (p = 0.043) and among physicians with ≤7 years (45.0%) or 8–14 years of experience (46.0%) than among those with >14 years (15.8%) (p = 0.016). The correct interpretation of a “2” ESCC score was also more common among neurosurgeons (66.7%) and orthopedic surgeons (50.0%) than among medical oncologists (22.2%) and radiation oncologists (20.0%) (p = 0.032).

3.4. Agreement with Statements

Agreement with the prognostic value of items included in the modified Tokuhashi score was ≥70%, except for the “number of bone metastases”, on which 48.8% of participants agreed (Table 4). Over 85% of the participants agreed with the prognostic value of the items included in the SINS score, and over 88% of the participants agreed with the recommendations from the NICE guideline, except for the one stating that all treating clinicians should participate in patient’s clinical assessment, on which 73.8% agreed (Table 4).
Agreement with the usefulness of the number of spinal metastases to estimate life prognosis was higher among physicians treating ≥ 14 patients with MSCC a year (67.7%) than among those treating ≤ 7 (46.7%) or 8–13 (21.1%) (p = 0.006).
Among participants with ≥14 years of practice, agreement with the inclusion of pain assessment in the clinical evaluation of MSCC (79.0%) was lower than among those with ≤7 years (100%) or 8–13 (94.7%) (p = 0.037). No other differences in these variables were found across specialties, number of patients treated annually, years of experience, private/public sector, and hospital complexity.

4. Discussion

Participants in this study were specialists involved in the management of SCC, who volunteered for a study assessing their clinical practice. Bearing this in mind, results showing relevant deviations from the gold standard practice are striking. Only 40% of hospitals systematically included the ESCC classification in their radiological reports. Over 77% of specialists knew what the SINS was, but only 60% used it in routine practice, and a significant proportion of them misinterpreted the meaning of the SINS and ESCC scores. Since multidisciplinary collaboration is paramount for the successful treatment of MSCC, the fact that only 34% of hospitals had a Board for MSCC and only 37% had set up a multidisciplinary protocol for patients with MSCC is a grave cause for concern. These results are in line with those from other countries [12,13,14,19] and suggest that there is room for improvement in the management of SCC in routine practice.
Results from this study do not support the assumption that the public sector provides better care for patients with MSCC; in fact, data suggest the opposite in terms of the use of SINS and availability of specialized Boards.
Some variations in results were also detected across hospital complexity and clinical experience. However, the most consistent differences were found among specialties. In general, physicians using interventional procedures (i.e., radiation oncologists, neurosurgeons, and especially orthopedic surgeons) were more familiar with the SINS and ESCC scores, used them more often, and were more accurate in interpreting their meaning than medical oncologists. This emphasizes the need for collaboration among specialists in routine practice.
Specialists with less than 14 years of experience interpreted the ESCC score more accurately than those with ≥14. This may suggest that more senior specialists rely less on a scale to assess the degree of spinal cord compression or that continued medical education should be reinforced for them, as is the case in other fields [20,21].
In general, there was a high degree of agreement with the prognostic value of most items included in the SINS and the Tokuhashi scores as well as with recommendations from the NICE guideline. However, many specialists did not use them in routine practice. This may reflect organizational obstacles in routine practice or disparity between knowledge and behavior.
Clinical experience was associated with agreement with some recommendations; specialists treating a higher number of patients with MSCC were more aware of the relevance of the number of spinal metastases to estimate life prognosis, whereas those with more years of practice tended to disregard the relevance of pain when assessing MSCC.
Due to sample size and the high number of comparisons, differences across participants’ characteristics should be interpreted with caution. This study aimed to identify potential gaps between current state-of-art recommendations and practice, in order to establish a hypothesis to be assessed in future studies with larger sizes and to assess whether actions should be undertaken to improve implementation of recommendations in routine practice. Therefore, at the design phase of this study, it was decided to prioritize sensitivity (i.e., identification of potential differences) and hence not to adjust results for multiples comparisons.
This study has additional limitations. Participants were not selected randomly, but volunteered to participate in a study on SMD exploring their knowledge and clinical practice. The societies endorsing the study have over 16,000 members, but only 80 volunteered. It is likely that participants are those who are most familiar and concerned with MSCC. Additionally, this study gathered specialists’ reports on their own clinical practice, as opposed to data on their actual clinical practice. Therefore, results from this study may underestimate deviations from the gold standard practice in actual clinical practice. This is a cause for concern, since it might suggest that a sizable proportion of patients with MSCC may be receiving sub-optimal management in routine practice.
Future studies should confirm these results. A registry allowing surveillance, benchmarking, and analysis of variability of results, factoring in patients’ characteristics and treating physicians, was successfully implemented in routine practice for patients with back pain referred from the Spanish NHS to private facilities [22,23,24,25]. Bearing in mind the devastating consequences of MSCC, the suffering it causes, and the importance to ensure optimal treatment and coordination among specialists involved in treating this condition, similar strategies should be implemented to monitor the actual management of patients with MSCC in routine practice. Additionally, actions should be undertaken to further implement and expand the use of evidence-based recommendations for the diagnosis and treatment of patients with MSCC and the impact of such actions, both on the use of these recommendations in routine practice and on patients’ outcomes, should be assessed.

5. Conclusions

In conclusion, this study suggests that there is room for improvement in the routine management of patients with spinal metastatic disease.

Author Contributions

Conceptualization, L.A.P.-R. and E.A.; methodology, L.A.P.-R., E.A., F.M.K. and A.R.; formal analysis, A.R.; investigation, L.A.P.-R. and E.A.; resources, F.M.K. and A.R.; data curation, A.R.; writing—original draft preparation, L.A.P.-R. and E.A.; writing—review and editing, F.M.K.; visualization, F.M.K.; supervision, F.M.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data as well as the script for statistical analyses will be available under request (aroyuela@idiphim.org).

Acknowledgments

The authors acknowledge the contribution of all the societies which endorsed the study and the specialists who agreed to participate. The authors thank Soraya García for the preparation of the questionnaire’s online version.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A. Questionnaire Completed by Participants in the Study

Date of birth
1Medical specialty.
Years in practice (post-certification)
2Sector:
  • National Health Service
  • Private
  • Both
3Only one hospital setting can be ascribed to each participant. If you work in more than one, please describe the main one:
4How many patients with metastatic spinal cord compression (MSCC) did you manage last year?
5Is a clinical guideline or other guiding document available for management of MSCC in your hospital?
6If a clinical guideline is not available, proceed to Question 7. If one is available, was the document agreed among more than one specialty involved in the diagnosis or treatment of MSCC?
Y/N/I am not sure
7Does your hospital have a specific Board for spine metastatic disease?
Y/N/Do not know
8If so, which specialties are represented on the board?
9Do you usually use an outcome score for patients with MSCC?
Y/N/Sometimes
10If you use one score, please indicate which:
  • Tokuhashi (original or revised)
  • Tomita, Bauer (original or revised)
  • Van der Linden
  • Variable (different scores at different times or across Departments),
  • Other
  • I don’t know
11In your clinical setting, which imaging technique is usually performed?
  • CT of the segment involved
  • MRI of the segment involved
  • Full-spine MRI
  • Other
12In your hospital, is the Epidural Spinal Cord Compression (ESCC) score included in the radiological reports?
  • Yes, always
  • Yes, occasionally
  • No
13How do you interpret “grade 1b” in the ESCC classification?
  • Bone-only disease
  • Epidural impingement, without deformation of the thecal sac
  • Deformation of the thecal sac without spinal cord abutment
  • Deformation of the thecal sac with spinal cord abutment, but without cord compression
  • Spinal cord compression, but with CSF visible around the cord
  • Spinal cord compression, no CSF visible around the cord
  • I am not sure
14How do you interpret “grade 2” in the ESCC classification?
  • Bone-only disease
  • Epidural impingement without deformation of the thecal sac.
  • Deformation of the thecal sac without spinal cord abutment
  • Deformation of the thecal sac with spinal cord abutment, but without cord compression
  • Spinal cord compression, but with CSF visible around the cord
  • Spinal cord compression, no CSF visible around the cord
  • I am not sure
15Are you familiar with the SINS (Spine Instability Neoplastic Score)?
Y/N/I am not sure
16Do you use SINS score in your clinical practice?
Y/N/Sometimes
17How do you interpret a SINS score of 3?
  • Spine stability
  • Potentially unstable
  • Unstable
  • I am not sure
18How do you interpret a SINS score of 10?
  • Spine stability
  • Potentially unstable
  • Unstable
  • I am not sure
19How do you interpret a SINS score of 15?
  • Spine stability
  • Potentially unstable
  • Unstable
  • I am not sure
20Select your degree of agreement with following sentences
(strongly disagree, disagree, neither agree nor disagree, agree, strongly agree):
Oncological prognosis is important to determine appropriate MSCC management
The number of bone metastases predicts life-expectancy in patients with MSCC
The score in general performance tools (such as the Karnofsky Performance Score or the Eastern Cooperative Oncology Group score) predicts life-expectancy in patients with MSCC
The existence of visceral metastases predicts life-expectancy in patients with MSCC
The type of primary tumor predicts life-expectancy in patients with MSCC
The degree of paresis predicts life-expectancy in patients with MSCC
MSCC evaluation requires a full-spine MRI
Clinical assessment of patients with MSCC should include a spinal cord neurological examination
Grading MSCC requires MRI
In patients with MSCC, all specialists involved should participate in patient assessment
Clinical assessment of patients with MSCC should include the assessment of strength and sensitivity in the limbs
Clinical assessment of patients with MSCC should include pain assessment
Clinical assessment of patients with MSCC should include the assessment of sphincter control
If the patient reports mechanical pain, spine stability should be assessed
The assessment of spine stability requires assessing whether lesions are blastic, lytic, or both
The assessment of spine stability requires assessing spinal alignment (new subluxations or deformity—scoliosis or kyphosis)
The assessment of spine stability requires assessing the degree of vertebral collapse
The assessment of spine stability requires assessing the involvement of facet joints
I herewith confirm that I completed this form in a single session, without prior assessment or consulting any online or printed information. I also confirm that, to the best of my knowledge, my responses reflect the clinical practice in my clinical environment and my own practice.

References

  1. Yang, L.; Wang, F.; Zhang, H.; Yang, X.; Li, J.; Qiao, R.; Zhang, G.; Hu, Y.; Zhang, H. Patient Characteristics Following Surgery for Spinal Metastases: A Multicenter Retrospective Study. Orthop. Surg. 2019, 11, 1039–1047. [Google Scholar] [CrossRef] [PubMed]
  2. Alpantaki, K.; Ioannidis, A.; Raptis, K.; Spartalis, E.; Koutserimpas, C. Surgery for spinal metastatic tumors: Prognostication systems in clinical practice (review). Mol. Clin. Oncol. 2020, 12, 399–402. [Google Scholar] [CrossRef] [PubMed]
  3. Quraishi, N.A.; Esler, C. Metastatic spinal cord compression. BMJ 2011, 342, d2402. [Google Scholar] [CrossRef] [PubMed]
  4. Loblaw, D.A.; Laperriere, N.J.; Mackillop, W.J. A population-based study of malignant spinal cord compression in Ontario. Clin. Oncol. 2003, 15, 211–217. [Google Scholar] [CrossRef] [PubMed]
  5. Overview|Metastatic Spinal Cord Compression in Adults: Risk Assessment, Diagnosis and Management|Guidance|NICE. Available online: https://www.nice.org.uk/Guidance/CG75 (accessed on 8 March 2021).
  6. Overview|Metastatic Spinal Cord Compression in Adults|Quality Standards|NICE. Available online: https://www.nice.org.uk/guidance/qs56 (accessed on 16 January 2022).
  7. Tokuhashi, Y.; Uei, H.; Oshima, M. Classification and scoring systems for metastatic spine tumors: A literature review. Spine Surg. Relat. Res. 2017, 1, 44–55. [Google Scholar] [CrossRef]
  8. Arana, E.; Kovacs, F.M.; Royuela, A.; Asenjo, B.; Nagib, F.; Pérez-Aguilera, S.; Dejoz, M.; Cabrera-Zubizarreta, A.; García-Hidalgo, Y.; Estremera, A. Metastatic versus osteoporotic vertebral fractures on MRI: A blinded, multicenter, and multispecialty observer agreement evaluation. J. Natl. Compr. Cancer Netw. 2020, 18, 267–273. [Google Scholar] [CrossRef]
  9. Arana, E.; Kovacs, F.M.; Royuela, A.; Asenjo, B.; Pérez-Ramírez, U.; Zamora, J.; Abraira, V.; Alcázar, L.; Alonso, A.; Álvarez, L.; et al. Agreement in the assessment of metastatic spine disease using scoring systems. Radiother. Oncol. 2015, 115, 135–140. [Google Scholar] [CrossRef]
  10. Arana, E.; Kovacs, F.M.; Royuela, A.; Asenjo, B.; Pérez-Ramírez, Ú.; Zamora, J.; Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis. Spine Instability Neoplastic Score: Agreement across different medical and surgical specialties. Spine J. 2016, 16, 591–599. [Google Scholar] [CrossRef]
  11. Arana, E.; Kovacs, F.M.; Royuela, A.; Asenjo, B.; Pérez-Ramírez, Ú.; Zamora, J.; the Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis. Agreement in Metastatic Spinal Cord Compression. J. Natl. Compr. Canc. Netw. 2016, 14, 70–76. [Google Scholar] [CrossRef]
  12. Brooks, F.M.; Ghatahora, A.; Brooks, M.C.; Warren, H.; Price, L.; Brahmabhatt, P.; De Vauvert, S.; John, C.; Farnworth, E.; Sulaiman, E.; et al. Management of metastatic spinal cord compression: Awareness of NICE guidance. Eur. J. Orthop. Surg. Traumatol. 2014, 24, 255–259. [Google Scholar] [CrossRef]
  13. McQuail, P.M.; McCartney, B.S.; Baker, J.F.; Jaadan, M.; McCabe, J.P. Management of Metastatic Spinal Cord Compression in Ireland: Are Surgeons Overlooked? Int. J. Spine Surg. 2018, 12, 428–433. [Google Scholar] [CrossRef] [PubMed]
  14. Shah, S.; Kutka, M.; Lees, K.; Abson, C.; Hadaki, M.; Cooke, D.; Neill, C.; Sheriff, M.; Karathanasi, A.; Boussios, S. Management of Metastatic Spinal Cord Compression in Secondary Care: A Practice Reflection from Medway Maritime Hospital, Kent, UK. J. Pers. Med. 2021, 11, 110. [Google Scholar] [CrossRef] [PubMed]
  15. Bilsky, M.H.; Laufer, I.; Fourney, D.R.; Groff, M.; Schmidt, M.H.; Varga, P.P.; Vrionis, F.D.; Yamada, Y.; Gerszten, P.C.; Kuklo, T.R. Reliability analysis of the epidural spinal cord compression scale. J. Neurosurg. Spine 2010, 13, 324–328. [Google Scholar] [CrossRef] [PubMed]
  16. Departamento de Métodos Cuantitativos en Economía y Gestión de la Universidad de Las Palmas. Clasificación de Hospitales Públicos Españoles Mediante el uso del Análisis de Conglomerados. Available online: https://www.sanidad.gob.es/en/estadEstudios/estadisticas/docs/NormaGRD2008/CLASIFICACIONHOSPITALESCLUSTER.pdf (accessed on 16 June 2022).
  17. Fisher, C.G.; DiPaola, C.P.; Ryken, T.C.; Bilsky, M.; Shaffrey, C.I.; Berven, S.H.; Harrop, J.S.; Fehlings, M.; Boriani, S.; Chou, D.; et al. A novel classification system for spinal instability in neoplastic disease: An evidence-based approach and expert consensus from the spine oncology study group. Spine 2010, 35, E1221–E1229. [Google Scholar] [CrossRef] [PubMed]
  18. Tokuhashi, Y.; Matsuzaki, H.; Oda, H.; Oshima, M.; Ryu, J. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine 2005, 30, 2186–2191. [Google Scholar] [CrossRef]
  19. Disch, A.C.; Kleber, C.; Redemann, D.; Druschel, C.; Liljenqvist, U.; Schaser, K.D. Current surgical strategies for treating spinal tumors: Results of a questionnaire survey among members of the German Spine Society (DWG). Eur. J. Surg. Oncol. 2020, 46, 89–94. [Google Scholar] [CrossRef]
  20. Hickey, G.L.; Grant, S.W.; Freemantle, N.; Cunningham, D.; Munsch, C.M.; Livesey, S.; Roxburgh, J.; Buchan, I.; Bridgewater, B. Surgeon length of service and risk-adjusted outcomes: Linked observational analysis of the UK National Adult Cardiac Surgery Audit Registry and General Medical Council Register. J. R. Soc. Med. 2014, 107, 355–364. [Google Scholar] [CrossRef]
  21. Tsugawa, Y.; Newhouse, J.P.; Zaslavsky, A.M.; Blumenthal, D.M.; Jena, A.B. Physician age and outcomes in elderly patients in hospital in the US: Observational study. BMJ 2017, 357, j1797. [Google Scholar] [CrossRef]
  22. Royuela, A.; Kovacs, F.M.; Seco-Calvo, J.; Fernández, B.; Abraira, V.; Zamora, J. Physician-related variability in the outcomes of an invasive treatment for neck and back pain. A multi-level analysis of data gathered in routine clinical practice. Int. J. Environ. Res. Public Heal. 2021, 18, 3855. [Google Scholar] [CrossRef]
  23. Campillo, C.; Casamitjana, M.; Carrillo-Arias, F.; Royuela, A.; Kovacs, F.M.; Abraira, V. Post-implementation surveillance of a non-pharmacological health technology within a National Health Service. Int. J. Technol. Assess. Heal. Care 2014, 30, 153–164. [Google Scholar] [CrossRef]
  24. Campillo, C.; Kovacs, F. The use of risk sharing tools for post adoption surveillance of a non pharmacological technology in routine practice: Results after one year. BMC Heal. Serv. Res. 2013, 13, 181. [Google Scholar] [CrossRef] [PubMed]
  25. Kovacs, F.M.; Seco, J.; Royuela, A.; Corcoll, J.; Abraira, V.; the Spanish Back Pain Research Network. Predicting the evolution of low back pain patients in routine clinical practice. Results from a registry within the Spanish National Health Service. Spine J. 2012, 12, 1008–1020. [Google Scholar] [CrossRef] [PubMed]
Table 1. Characteristics of participants and their work settings.
Table 1. Characteristics of participants and their work settings.
Age 1 45.59 (10.7) [27–68]
Years of experience 2As a specialist in training (n = 3)4 (3; 5) [3–5]
As a certified specialist (n = 77)13 (7; 24) [1–34]
Specialty 3Orthopedic Surgery32 (40.0)
Radiation Oncology 20 (25.0)
Medical Oncology18 (22.5)
Neurosurgery6 (7.5)
Radiology3 (3.8)
Rehabilitatation1 (1.3)
Number of patients with MSCC treated per year 3≤720 (26.0)
8–1319 (24.7)
≥1438 (49.4)
Private/public sector 3Only National Health Service 48 (60.0)
National Health Service and private practice25 (31.3)
Only private practice7 (8.8)
Hospital ownership 3National Health Service 59 (73.8)
Other govermental entities14 (17.5)
For-profit private entities4 (5.0)
Non profit private entities3 (3.8)
Hospital management 3Govermental (National Health Service or other governmental entities)66 (82.5)
Private 14 (17.5)
Complexity level of the hospital 3Level 1 1 (1.3)
Level 2 14 (17.5)
Level 312 (15.0)
Level 431 (38.8)
Level 522 (27.5)
Hospital treating patients from the National Health Service 3Yes 76 (95.0)
No4 (5.0)
Hospital has a protocol for clinical management of SMD 3Yes31 (38.8)
No41 (51.3)
Unknown8 (10.0)
Hospital has a multidisciplinary protocol for management of SMD 3Yes30 (37.5)
No18 (22.5)
Unknown32 (40.0)
Hospital has a Board for SMD 3Yes27 (33.8)
No53 (66.3)
Number of specialties represented in the Board 311 (1.3)
37 (8.8)
420 (25.0)
MSCC: Metastatic Spinal Cord Compression; 1: Mean (SD) [range]; 2: Mean (P25; P75) [range]: 3: n (%); see the text for details on differences found across private/public sectors.
Table 2. Description of clinical practice; n (%).
Table 2. Description of clinical practice; n (%).
All Participants (n = 80)MO
(n = 18)
RO
(n = 20)
NS
(n = 6)
OS
(n = 32)
RX
(n = 3)
RS
(n = 1)
Is familiar with the Spine Instability Score (SINS)Yes62 (77.5)9 (50.0)17 (85.0)4 (66.7)28 (87.5)3 (100)1 (100)
No18 (22.5)9 (50.0)3 (15.0)2 (33.3)4 (12.5)0 (0.0)0 (0.0)
Uses SINS in routine practiceYes, systematically48 (60.0)4 (22.2)11 (55.0)4 (66.7)26 (81.3)2 (66.7)1 (100)
Yes, occasionally 9 (11.3)1 (5.6)4 (20.0)0 (0.0)3 (9.4)1 (33.3)0 (0.0)
No23 (28.8)13 (72.2)5 (25.0)2 (33.3)3 (9.4)0 (0.0)0 (0.0)
Uses an outcome score in patients with MSCCYes, systematically47 (58.8)7 (38.9)12 (60.0)4 (66.7)24 (75.0)0 (0.0)0 (0.0)
Yes, occasionally 12 (15.0)2 (11.1)4 (20.0)1 (9.4)3 (9.4)1 (33.3)1 (100)
No21 (26.3)9 (50.0)4 (20.0)1 (16.7)5 (15.6)2 (66.7)0 (0.0)
Outcome score used in the hospital, if anyVaries across Departments27 (33.8)
Tokuhashi22 (27.5)
Tomita10 (12.5)
Other8 (10.0)
Do not know13 (16.3)
Imaging procedure used in the hospital to assess patients with MSCC Full-spine MRI57 (71.3)
MRI involved segment18 (22.5)
CT segment involved2 (2.5)
Other3 (3.8)
Radiological reports produced in the hospital include the ESCC scoreYes, systematically14 (17.5)
Yes, occasionally18 (22.5)
No48 (60.0)
MO: Medical Oncologists. RO: Radiation Oncologists. NS: Neurosurgeons. OS: Orthopedic Surgeons. RX: Radiologists. RS: Rehabilitation Specialist. See the text for details on the differences found across hospital complexity, specialties, and private/public sectors.
Table 3. Appropriateness of the interpretation of the scores in the SINS and the ESCC classification.
Table 3. Appropriateness of the interpretation of the scores in the SINS and the ESCC classification.
Correct Interpretation of the SINS Score (%)
All Participants (n = 80)MO
(n = 18)
RO
(n = 20)
NS
(n = 6)
OS
(n = 32)
RX
(n = 3)
RS
(n = 1)
SINS score = 365.033.365.066.778.1100100
SINS score = 1055.527.855.066.768.8100100
SINS score = 1570.044.470.066.781.3100100
Correct interpretation of the ESCC score (%)
ESCC score = 1b30.0016.715.016.746.967.70.0
ESCC score = 237.522.220.066.750.033.3100
MO: Medical Oncologists. RO: Radiation Oncologists. NS: Neurosurgeons. OS: Orthopedic Surgeons. RX: Radiologists. RS: Rehabilitation Specialists. See the text for details on the differences found across specialties and years of experience.
Table 4. Agreement with the items to be assessed in patients with MSCCC (n = 80).
Table 4. Agreement with the items to be assessed in patients with MSCCC (n = 80).
ItemN (%)
Items related to prognosis
Oncologic prognosis 75 (93.8)
Number of spinal metastases39 (48.8)
Score in tools (e.g., KPS or ECOGS)73 (91.3)
Visceral metastases67 (83.8)
Type/location of primary tumor58 (72.5)
Degree of paresis56 (70.0)
Items related to spine stability
Mechanical pain 69 (86.3)
Type of bone lesion (lytic/blastic/mixed)73 (91.3)
Spinal alignment78 (97.5)
Degree of vertebral body collapse76 (95.0)
Involvement of facet joints77 (96.3)
Items included in the recommendations from DG-75 NICE clinical guideline
Full spine MRI to assess compression76 (95.0)
Neurologic examination77 (96.3)
MRI to assess degree of compression78 (97.5)
Clinical assessment of degree of compression by all treating clinicians59 (73.8)
Assessment of limb strength and sensitivity79 (98.8)
Assessment of pain71 (88.8)
Assessment of sphincter control79 (98.8)
KPS: Karnofsky Performance Score; ECOGS: Eastern Cooperative Oncology Group Score. See the text for details on differences found across physicians’ number of years in practice and physicians’ number of patients with SMD treated annually. See Appendix A for details on how the questions on the items included in the guideline were formulated.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pérez-Romasanta, L.A.; Arana, E.; Kovacs, F.M.; Royuela, A. The Management of Metastatic Spinal Cord Compression in Routine Clinical Practice. Cancers 2023, 15, 2821. https://doi.org/10.3390/cancers15102821

AMA Style

Pérez-Romasanta LA, Arana E, Kovacs FM, Royuela A. The Management of Metastatic Spinal Cord Compression in Routine Clinical Practice. Cancers. 2023; 15(10):2821. https://doi.org/10.3390/cancers15102821

Chicago/Turabian Style

Pérez-Romasanta, Luis Alberto, Estanislao Arana, Francisco M. Kovacs, and Ana Royuela. 2023. "The Management of Metastatic Spinal Cord Compression in Routine Clinical Practice" Cancers 15, no. 10: 2821. https://doi.org/10.3390/cancers15102821

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop